Report topline results for the AR-15512 Phase 2b clinical study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 12 Jan 2021
- Due
- 30 Sep 2021
- Delivered
- September 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Topline readout expected Q3 2021.”
What we found
Evidence strength A What the grades mean
Aerie Pharmaceuticals reported positive topline results for the AR-15512 Phase 2b clinical study (COMET-1) in September 2021, which falls within the third quarter of 2021.
-
A Aerie Pharmaceuticals Inc. 10-Q filed 2021-11-05
“In September 2021, the Company reported positive topline results of its Phase 2b clinical study, named COMET-1, for AR-15512.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- AR-15512 Phase 2b topline results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Aerie Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C337553-021889 · Corrections policy